PDS Biotech Q2 FY26 net loss widens to $9.8 million; R&D expense falls 22.49% to $3.3 million

PUBT · 1d ago
PDS Biotech Q2 FY26 net loss widens to $9.8 million; R&D expense falls 22.49% to $3.3 million
  • PDS Biotech posted a Q2 net loss of USD 9.8 million, or USD 0.18 a share, versus a loss of USD 9.4 million.
  • R&D expense fell to USD 3.3 million from USD 4.2 million on lower clinical trial, manufacturing and personnel costs.
  • Operating costs dropped to USD 6.5 million from USD 7.6 million; net interest expense climbed to USD 3.3 million from USD 1.8 million.
  • Cash and equivalents were USD 5.6 million at June 30, 2026, down from USD 26.7 million at Dec. 31, 2025.
  • Strategy refocus prioritizes tumor-targeted IL-12 program PDS0301; internal investment in PDS0101 stops, including ending VERSATILE-003 Phase 3.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130830PRIMZONEFULLFEED9809169) on August 13, 2026, and is solely responsible for the information contained therein.